Introduction
Today, dose-intensive chemotherapy followed by peripheral blood stem cell transplantation (PBSCT) is common practice in the treatment of a variety of hematopoietic malignancies. 1 In patients with multiple myeloma, the single or tandem administration of high-dose melphalan followed by a PBSCT is a standard treatment regimen. [2] [3] [4] A major advance in the attempt to mobilize blood stem cells from the BM into the peripheral blood was the use of G-CSF in combination with chemotherapeutic agents. [5] [6] [7] It is evidence that an increased number of transplanted peripheral blood stem cells contributes to a more rapid hematological recovery and thus lowers the incidence of clinical complications and costs associated with transfusions, antibiotic therapy and hospital stay. 8, 9 Clinical trials with patients suffering from solid tumors have shown that the efficiency of stem cell mobilization is improved when EPO is added to G-CSF treatment after the mobilizing chemotherapy, confirming in vitro and in vivo observations that the mobilizing effect of G-CSF is augmented by EPO. [10] [11] [12] In this randomized, prospective study, we extended these observations to patients with multiple myeloma and compared the effect of adding EPO to G-CSF with regard to the number of PBSCs mobilized and the number of aphereses needed for successful PBSCT. Furthermore, the time interval needed for the recovery of peripheral blood cells after PBSCT as well as the incidence of infections during neutropenia and the need for supportive treatment in both groups was investigated. As autologous PBSCT is a very expensive procedure, we additionally evaluated the impact of EPO on the costs for diagnostics, supportive treatment and hospital stay during mobilization and PBSCT.
Materials and methods

Patient eligibility
Patients younger than 70 years with the diagnosis of multiple myeloma (Durie and Salmon stages II and III) 13 who were scheduled for high-dose chemotherapy were eligible. The criteria for inclusion were hemoglobin o13 g/100 ml at the time of randomization and a performance status grade o3 according to the Eastern Cooperative Oncology Group. 14 The criteria for exclusion were severe cardiac, pulmonary, hepatic or renal dysfunction, uncontrolled elevated blood pressure, occurrence of a thromboembolic event within the last 12 months and treatment with EPO within the last 4 weeks before randomization. The study was approved by the institution's research ethics committee and written informed consent was obtained from all the patients.
Treatment
Treatment consisted of four cycles of induction chemotherapy composed of a combination of idarubicin and dexamethasone, a combination of cyclophosphamide, adriamycin and dexamethasone or dexamethasone alone. Then the patients were randomly assigned to the alternative growth factor treatment and the mobilizing chemotherapy was started. This chemotherapy (IEV) included ifosfamide 2500 mg/m 2 over 3 h on days 1-3, etoposide 150 mg/m 2 i.v. on days 1-3 and epirubicin 100 mg/m 2 . Patients up to the age of 60 received the regimen at a 100% dosage, for patients older than 60 years, the dosage was reduced to 75% following a common dosereduction scheme. Upon completion of IEV, patients were discharged from hospital in the absence of fever or relevant nonhematologic toxicities.
Application of hematopoietic growth factors
Patients randomized to G-CSF were treated with subcutaneous injections of recombinant human G-CSF (Filgrastim, Amgen, Munich, Germany) at a dose of 5 mg/kg/ day twice daily (corrected to the closest 300 or 480 mg vial). G-CSF was administered starting on the third day after chemotherapy until the last day of leukapheresis.
Patients randomized to G-CSF þ EPO additionally received subcutaneous injections of recombinant human EPO-a (Erypo, Janssen-Cilag GmbH, Neuss, Germany) at a dose of 150 IE/kg beginning at day 1 after chemotherapy and continued every other day until the stem cell collection was completed.
Stem cell collection
In the absence of fever, patients were admitted to the hospital for stem cell apheresis on day 10 following the mobilizing chemotherapy. If necessary, the admission occurred earlier in case of neutropenic fever. When the post-nadir WBC count exceeded 1.0 Â 10 9 /l, the number of CD34 þ cells was determined daily by flow cytometry as described. 15 Leukaphereses were started on the day the CD34 þ cell count reached 10 Â 10 6 /l. Approximately 10 l of blood per patient was processed using a continuous flow cell separator (Cobe Spectra, Cobe, Lakewood, CO, USA) at an average flow rate of 55 ml/min. Leukaphereses were repeated if necessary on consecutive days to obtain at least 6 Â 10 6 CD34 þ cells per kgbw (2 Â 10 6 cells each transplantation and one backup). The harvested cells were immediately cryopreserved in 10% dimethyl sulfoxide (DMSO, Sigma, St Louis, MO, USA) and were stored in liquid nitrogen freezers (À196 1C).
Dose-intense chemotherapy
Approximately 4 weeks after the stem cell collection, the patients proceeded to the first course of dose-intensive chemotherapy. Patients younger than 60 years received 100 mg/m 2 per day on two consecutive days; this dosage was reduced to 70 mg/m 2 per day in the elderly. In the first course of high-dose chemotherapy, 38% of the patients in the EPO group versus 66% of the patients in the G-CSF group received the less myelosuppressive conditioning regimen with 140 mg/m 2 melphalan instead of 200 mg/m 2 . Forty-eight hours after the second infusion of melphalan, PBSCs were infused. G-CSF was administered from the second day and was continued until hematologic recovery was achieved. Patients younger than 60 years at high genetic risk for early progression as defined by the deletion of chromosome 13 by conventional cytogenetics were planned for allogeneic PBSCT after the first cycle of highdose chemotherapy, provided that a suitable donor was available. Patients without chromosome 13 deletion were treated with a second course of high-dose chemotherapy. Melphalan 140 mg/m 2 was administered to 55% of the patients in the EPO group and to all patients in the G-CSF group. After PBSCT, all patients were discharged from hospital in the absence of fever when the WBC count and the platelet count exceeded 1 Â 10 9 /l and 20 Â 10 9 /l, respectively.
Diagnostics
In patients developing febrile neutropenia, blood and urine were analyzed microbiologically and a chest X-ray was performed. Corresponding to clinical symptoms, a mucosa smear or a stool sample was analyzed microbiologically. If fever continued despite antibiotic therapy, a computed tomography of the lung was performed to identify fungal infections.
Supportive care
During the period of myelosuppression, all patients were given packed RBCs when the hemoglobin concentration fell below 8 g/100 ml or a symptomatic anemia occurred. Platelet transfusions were given at a platelet count below 10 Â 10 9 /l or during bleeding episodes. As antimicrobial prophylaxis after high-dose melphalan, oral ciprofloxacin and fluconazole were administered. All patients developing febrile neutropenia were treated with i.v. broadspectrum antibiotics (the first-line antibiotics consisted of piperacillin and sulbactam); in case of persisting fever over 48 h and negative microbiological testing, the empiric antibiotic treatment was changed to meropenem and vancomycin. Empiric antifungal therapy with voriconazole was initiated after 96 h of persisting fever or in case of proven, probable or possible invasive fungal infections detected by bronchoalveolar lavage or computed tomography of the lung.
Assessment of mobilization effectiveness and toxicity Mobilization success was measured by the total number of CD34 þ cells/kgbw collected and by the number of leukaphereses needed to obtain the threshold number of 6 Â 10 6 CD34 þ cells/kgbw. WHO toxicity criteria were used to assess grade and frequency of adverse events occurring after the mobilizing regimen and after high-dose melphalan. The duration of the hospital stay was registered as well as the number of days necessary for the adminis-tration of the mobilization chemotherapy, the number of days necessary for leukaphereses, the number of days due to earlier admission to hospital because of febrile neutropenia and the number of days after the implementation of high-dose melphalan until discharge of the patients. The time interval needed for the hematopoietic recovery after SCT was assessed by the number of days during which the leukocyte count was less than 1.0 Â 10 9 /l, the hemoglobin value was less than 8 g/100 ml and the platelet count was less than 20 Â 10 9 /l. With regard to supportive treatment, we evaluated the number of RBC and platelet transfusions as well as the number of days on antibiotic treatment. After SCT, we recorded the number of G-CSF injections until the hematopoietic recovery was achieved.
Cost analysis
Costs were measured in physical quantities obtained from detailed observation of each patient's medical record. G-CSF, EPO, antibiotics unit cost and transfusion unit cost were the purchase prices for the hospital. The prices for leukaphereses, microbiological analyses and radiological investigations were set by the relevant department. The per diem room cost was the official price for our institution.
Statistical analysis
Statistical analysis was performed using MINITAB statistical software (Minitab Inc., State College, PA, USA). Comparisons between both treatment regimens were performed using the two-sample t-test. In addition, Fisher's exact test and the w 2 test were applied to evaluate significance in the occurrence of febrile neutropenia and the mobilization success in both groups. Correlation was calculated and graphs were performed using GraphPad Prism (GraphPad Software Inc., San Diego, CA, USA). P-values o0.05 were deemed significant.
Results
Characteristics of the patients and treatments
Between May 2004 and January 2006, twenty-eight patients with multiple myeloma Salmon Durie stage II/III who were admitted to our department for mobilizing chemotherapy were enrolled into the clinical trial. The baseline characteristics of the patients at the time of randomization are summarized in Table 1 . All patients were comparable in terms of age, previous treatment and hematologic characteristics. In addition, there was no significant difference in the patients' body weight (74.9±10 kg in the EPO group versus 78.9±12 kg in the G-CSF group; P ¼ 0.35).
Of all enrolled patients, 14 patients were randomly assigned to receive G-CSF treatment and 14 were randomized to receive G-CSF and EPO. Treatment schedule and patient distribution are shown in Figure 1 . Two patients of the G-CSF group had to be excluded because G-CSF was not injected according to the study protocol.
On day 10, the patients were admitted to hospital for the stem cell harvest. After successful stem cell collection and recovery, the patients were subsequently referred for the first high-dose melphalan therapy. One patient in the EPO group was unable to undergo high-dose chemotherapy due to deterioration of his renal function during neutropenic fever and septicemia after IEV chemotherapy. Six patients in the G-CSF group did not undergo a second course of high-dose melphalan for the following reasons: four patients with chromosome q13 deletion were planned for allogeneic PBSCT, one patient showed an insufficient tumor response and in one patient the stem cell harvest was only sufficient for one single transplantation. In the EPO group, four patients did not proceed to a second course of intense chemotherapy because they were scheduled for allogeneic PBSCT and one patient had an insufficient tumor response. Eventually, six patients in the G-CSF and nine patients in the EPO group received a second course of high-dose melphalan. Effect of G-CSF and G-CSF þ EPO on leukocyte and CD34 þ cell count Figure 2a shows the number of WBCs on day 0 (before mobilization) and on days 10 and 11 upon completion of the mobilizing regimen. There was no significant difference between the leukocyte count on day 0 (P ¼ 0.797) and on day 10 (P ¼ 0.431) within the two different treatment groups. The CD34 þ cell count per ml of blood on days 10 and 11 after mobilizing chemotherapy and stimulation with either G-CSF or G-CSF þ EPO is illustrated in Figure 2b . The CD34 þ cell count in the G-CSF þ EPO group is slightly higher than in the G-CSF-alone group, but not statistically significant (day 10: P ¼ 0.3; day 11: P ¼ 0.07).
Effect of G-CSF and G-CSF þ EPO on stem cell mobilization All patients in both arms underwent leukapheresis. As shown in Table 2 , stem cell harvest was initiated at a mean of 10 days after IEV treatment (G-CSF group: range 9-10; EPO group: range 9-10; P ¼ 0.24). Overall, a lower number of leukaphereses yielded a higher number of CD34 þ cells/ kgbw in the G-CSF þ EPO-treated patients, as compared with patients receiving G-CSF alone. In detail, all patients in the combination G-CSF þ EPO group reached the target number of PBPCs (46 Â 10 6 CD34 þ cells/kgbw), whereas two patients in the G-CSF alone group failed the threshold. Six out of 12 patients (50%) in the G-CSF group versus 11 out of 14 patients (79%) in the EPO group achieved the projected threshold already with the first leukapheresis, whereas 4 out of 12 patients (33%) mobilized with G-CSF alone and 3 out of 14 patients (21%) mobilized in combination with EPO needed two leukaphereses for successful stem cell harvest. In patients treated with G-CSF alone, a total of 12.6 Â 10 6 CD34 þ cells/kgbw (range 4-42) was collected, patients in the EPO group achieved a total of 15.4 Â 10 6 CD34 þ cells/kgbw (range 6-64). The mean processed blood volume per single apheresis was not different in both groups.
Treatment-related toxicity and supportive care during mobilization In general, treatment with G-CSF or G-CSF þ EPO was well tolerated. The most frequent adverse event was mild-to-moderate bone pain, especially in the region of the 
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Collection of PBSCs pelvis, and was equally distributed between both groups. In two patients in the G-CSF þ EPO and three patients in the G-CSF-alone group, the WBC count exceeded 15 Â 10 9 cells/l, with one patient in the EPO group suffering from spleen enlargement that declined with the normalization of the leukocytes. There were no fatal or life-threatening events attributable to the growth factor treatment. Details of treatment-related toxicity and supportive treatment are shown in Table 3 . Grade 3-4 neutropenia occurred in all evaluable patients in both groups. Anemia (grades 3-4) occurred in 42% of the patients in the G-CSF alone and in 50% of the patients in the EPO group. No thrombocytopenia (grades 3-4) was recorded in the EPO group, whereas in 17% of the patients pretreated with G-CSF alone, thrombocytes values fell below 20 Â 10 9 /l. A total of 58% of the patients mobilized with G-CSF alone suffered from febrile neutropenia as compared with 36% of the patients treated with G-CSF þ EPO and had to be admitted to the hospital. One patient in the EPO group with previously existing reduced renal function grade 2 developed neutropenic fever and septicemia upon IEV chemotherapy leading to worsening of her renal function to grade 3 and thus exclusion from the high-dose chemotherapy protocol.
Patients needed antibiotic therapy at an average of 2.4 (range 0-7) and 4.7 days (range 0-15) in the G-CSF þ EPO group and the G-CSF group, respectively. In the G-CSF group, 5 out of 12 patients (41%) required blood transfusions (1.0 transfusion per patient) and 2 patients (17%) needed platelet transfusions (0.2 transfusion per patient) compared with the EPO group, in which 7 out of 14 patients (50%) received RBC transfusions (1.0 transfusion per patient) and 1 patient (7%) was treated with platelet transfusion (0.1 transfusion per patient).
Engraftment parameters and supportive care after high-dose melphalan and auto-SCT The data of engraftment parameters, major toxicities and supportive therapy after transplantation are shown in Table 4 . There was no statistical significance concerning the number of transplanted CD34 þ cells between both treatment groups.
The average duration of severe neutropenia was approximately 7 days in both groups. The time needed for leukocyte engraftment after the first and second transplantation and the number of days with a hemoglobin level o8.0 g/100 ml was equally distributed within both treatment groups. The time interval until the recovery of the platelet count above 20 Â 10 9 /l was approximately 1 day shorter when G-CSF þ EPO-mobilized stem cells were transplanted, although this difference was not statistically significant. After transplantation, fewer patients in the EPO group compared with the G-CSF-alone group developed febrile neutropenia (72% in the G-CSF-alone group versus 32% in the G-CSF þ EPO group; P ¼ 0.02), and thus the number of days on i.v. antibiotic treatment was shorter (on Table 4 Engraftment parameters, major toxicity and supportive therapy after high-dose chemotherapy and SCT average 6.1 days in the G-CSF-alone and 2.3 days in the G-CSF þ EPO group; P ¼ 0.02). A total of 66% of the patients in the G-CSF group needed RBC and platelet transfusion after the first transplantation compared with 38% of the patients in the G-CSF þ EPO group. After the second transplantation, the need for RBC transfusion was recorded in 50% of the patients mobilized with G-CSF alone and in 11% of the patients mobilized with G-CSF þ EPO. Platelet transfusions were given to all patients (100%) within the G-CSF group and to 44% of the patients within the G-CSF þ EPO group, and on average 1.2 and 0.5 platelet transfusions were given (P ¼ 0.02), respectively. The number of G-CSF injections was similar in both treatment groups and after both transplantations. The duration of the hospital stay was shorter in the G-CSF þ EPO group compared with the G-CSF-alone group (15.2±2.3 and 17.8±5.2 days; P ¼ 0.06).
Relationship between recovery after transplant and the number of CD34 þ cells transplanted Eighteen and 22 PBSC transplantations were performed in the G-CSF-alone and G-CSF þ EPO groups, respectively. In spite of the eightfold variation in the number of CD34 þ cells transplanted (per kgbw), the time to recovery of WBC to 1.0 Â 10 9 /l was highly predictable between 10 and 15 days after transplantation in the G-CSF-alone group and between 9 and 13 days in the G-CSF þ EPO group. In both arms, a negative linear correlation (Pearson correlation coefficient ro1) was found between the number of CD34 þ cells transplanted per kgbw and the time to recovery of WBC to 41.0 Â 10 9 /l as well as the number of days with a hemoglobin o8.0 g/100 ml (see Figure 3) . However, the latter correlation was not significant (P40.05). With regard to the platelet recovery, there was no correlation (r ¼ 0.08) between the number of CD34 þ cells transplanted and the number of days with platelets o20 Â 10 9 /l in the G-CSF group, but a medium negative correlation (r ¼ À0.39; P ¼ 0.04 one-tailed) in the G-CSF þ EPO group.
Cost analysis
The calculation of the expenses from mobilization and stem cell harvest can be seen in Figure 4a . The increased costs for the administration of EPO in combination with G-CSF are compensated by the reduction of the costs resulting from less diagnostics and antibiotics needed and a reduced number of transfusions. Additionally, a shorter hospital stay and fewer aphereses resulted in a further cost reduction in the EPO group. The comparison of the final total of all costs indicates that administration of G-CSF þ EPO reduces the expenses during the mobilization period as compared with G-CSF alone, although the result is not statistically significant (P ¼ 0.53). Figure 4b shows the comparison between the first and second high-dose melphalan therapy. Cost for diagnostics, transfusions and the hospital stay are significantly decreased in the EPO group as compared with the G-CSF group. The overall expenses for one transplantation are significantly lower in the G-CSF þ EPO group than in the G-CSF-alone group (h9022 versus h11166; P ¼ 0.018).
Discussion
A successful stem cell harvest is a prerequisite for PBSCT. To mobilize and collect a sufficient number of peripheral blood stem cells, various chemotherapy regimes combined with the administration of G-CSF have been established, 6, 7, 16 of which the combination of ifosfamide, epirubicin and etoposide proved to be highly effective for a successful mobilization. 17 To maximize the efficacy of stem cell collection-particularly in patients pretreated with chemotherapy in whom it may be difficult to attain the requested number of stem cells-and to reduce the necessary expenditures for treatment, a variety of cytokines (G-CSF þ SCF; G-CSF þ EPO) were used in clinical trials. 10, 11, [18] [19] [20] Pierelli et al. 10 showed in patients with ovarian cancer pretreated with epirubicin, paclitaxel and cisplatin that the collection of a higher number of CD34 þ cells with a lower number of necessary leukaphereses was achieved by the administration of G-CSF in combination with EPO compared with G-CSF alone. In the study of Oliveri et al.
11 that comprised heavily pretreated patients suffering from mainly hematologic neoplasias, the number of CD34 þ cells could be enhanced by the additional use of EPO to G-CSF, but no effect on the number of leukaphereses was seen. In patients with breast cancer 19 and advanced gynecological malignancies, 10 the addition of EPO to G-CSF influenced neither the number of collected CD34 þ cells nor the number of leukaphereses. In our study, patients treated with the combination of G-CSF and EPO tended to mobilize CD34 þ cells more efficiently, resulting in a higher cell yield with fewer leukaphereses needed as compared with the patients mobilized with G-CSF alone, although the result was due to the low patient number not statistically significant. In none of the studiesincluding ours-was it possible to reduce the number of RBC transfusions despite the use of EPO.
We are the first to study the effect of the addition of EPO to G-CSF during the mobilization process on the engraftment of the transplanted cells after two auto-SCTs and the influence on the occurrence of febrile neutropenia, amount of supportive treatment and the duration of the hospital stay. After transplantation of a comparable number of CD34 þ cells in both arms, we found that patients treated with G-CSF þ EPO had a lower incidence of febrile neutropenia and needed fewer antibiotics, although there was no significant difference in neutrophil recovery between both arms. Patients within the G-CSF group received on average a lower dose of conditioning chemotherapy. This rules out that decreased myelosuppression or increased endogenous BM recovery could have shortened the vulnerable period of the G-CSF þ EPO-treated patients.
The expression of the target receptor for EPO has been shown in cells other than erythroid progenitors including T and B lymphocytes, 21 and in vitro and in vivo studies have investigated the effects of recombinant human EPO on cellmediated and humoral immunity. 22 EPO promotes the proliferation of B cells, what could be responsible for an increased number of immature and mature B cells in the graft. [21] [22] [23] [24] Our data suggest further that the quality of the stem cell pool mobilized by G-CSF þ EPO might be different compared with G-CSF alone. Several studies show that the versatile mobilization process after G-CSF administration implements a variety of cellular and molecular responses such as degradation of extracellular matrix proteins, cleavage of adhesion receptors expressed on hematopoietic stem cells and within the extracellular matrix and indirect activity on stromal cells. [25] [26] [27] In fact, the disruption of the CXCL12-CXCR4 interaction by either degradation of CXCL12 by G-CSF 28 or specific blocking with antagonists 29 seems to be one key factor, as this results in a rapid hematopoietic stem cell mobilization even without G-CSF. Of special interest in this context is the study of Abraham et al., 30 who showed that the application of different CXCL12 antagonists, binding to different sites of the protein, changes the pool of mobilized colonyforming cells (CFC). 4F-benzoyl-TN14003 significantly mobilizes more erythrocyte progenitors than AMD3100. 30 The question if EPO acts as direct stimulant for hematopoietic stem cell mobilization or has indirect activity remains speculation, however. The effect of EPO on platelet recovery following allogeneic PBSCT was previously investigated but results are inconsistent, and in most of the studies, recombinant human EPO failed to accelerate platelet reconstitution. 31, 32 In this context, Hogge et al. 33 performed a careful analysis of leukapheresis collections from 90 cancer patients and found that the number of CD34 þ cells in harvests from different patients was correlated with the number of total CFC and CFCmegakaryocyte, and the transplantation of all three cell types above threshold values predicted rapid platelet recovery. 33 To identify a possible difference of type or number of progenitor cells mobilized into the peripheral blood, we examined CFC and long-term-culture-initiating cells analyzing the blood of seven patients in each treatment group. No significant difference was found, only the CFC-GM number in the G-CSF þ EPO group was slightly increased. 15 However, CFC assays do not allow the detection of lymphatic progenitors. We speculate, however, that EPO might have increased the number of B cells, lymphatic progenitors and megakaryocyte progenitors in the graft transplanted. As we cannot provide data on CFClymphoid and CFC-megakaryocyte numbers in the leukapheresis product or additional FACS data of the peripheral blood compartment, this speculation remains unproven.
Cost effectiveness in the health care system is becoming increasingly important, and besides the proof of efficacy, cost analysis of new treatment protocols is of relevance. 34 Despite the higher outlay for the additional use of EPO, the overall costs are slightly lower in the G-CSF þ EPO group than in the G-CSF-alone group, mainly because of a more sufficient stem cell collection and a shorter hospital stay, but the difference is not statistically significant. Further on, it was our aim to examine how the additional administration of EPO during mobilization influences the costs arising from two courses of high-dose melphalan therapy (including expenses for diagnostics, supportive treatment and hospital stay). Although patients in both study arms received a comparable number of CD34 þ cell/kgbw after melphalan therapy, the overall costs per transplant were significantly lower in the G-CSF þ EPO arm because of the reduced need for supportive therapy. Previously, it was shown that the transplantation of high numbers of CD34 þ cells is cost effective. 35 Our study extends this observation Table 4 , the number of CD34 þ cells transplanted (per kgbw) is plotted on the y axis against the x axis (i) the first day with WBC counts 41 Â 10 9 /l (left graphs), (ii) the number of days with platelet counts o20/nl (middle graphs) and (iii) with a hemoglobin value o8.0 g/100 ml (right graphs). Data from patients of the G-CSF group are shown in the upper graphs; data from patients of the G-CSF þ EPO group are shown in the lower graphs. The Pearson correlation coefficient r and the significance of the correlation are additionally indicated; Po0.05 is considered significant. and points to the fact that transplantation of the right, that is, G-CSF þ EPO-mobilized, CD34
þ cells is cost saving and contributes to an improved clinical outcome of the patients possibly through factors like an enhanced reconstitution of the immune system or regeneration of the megakaryocytes.
In summary, we suggest that the addition of EPO to the standard treatment with G-CSF in mobilizing procedures should be considered in future treatment protocols because it is effective and cost efficient with regard to two cycles of high-dose melphalan therapy. treated either with GCSF alone or with GCSF þ EPO are indicated. P-values were calculated with the two-sample t-test and were 40.05 if not otherwise indicated.
